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Abstract 20 
This study was aimed to evaluate the effect of Porcine circovirus 2 (PCV2) sow 21 
vaccination on cell-mediated immune responses in sows and their progeny. At 7 weeks 22 
before farrowing, fifteen PCV2 PCR negative pregnant sows with medium-low antibody 23 
values were selected and randomly distributed in two groups according to the antibody 24 
levels. Seven sows were vaccinated with a commercial PCV2 vaccine and eight were 25 
injected with phosphate-buffered saline at 6 and 3 weeks before farrowing. Blood samples 26 
were taken from sows and their piglets (n=90) during the study duration. PCV2 DNA and 27 
antibodies were tested in sera, and cytokine (IFN-α, IFN-γ, IL-12p40, TNF-α, IL-1β, IL-28 
8, IL-4, IL-6 and IL-10) levels were assessed in supernatant from cultured peripheral 29 
blood mononuclear cells. All sows and piglets were negative by PCV2 PCR throughout 30 
the study. Significantly higher PCV2 antibody levels were detected in vaccinated sows 31 
after vaccination and in their offspring after colostrum ingestion compared to the non-32 
vaccinated counterparts. Vaccinated sows did not show significant differences in cytokine 33 
secretion levels at farrowing compared to unvaccinated dams. In contrast, piglets from 34 
vaccinated sows had significantly higher levels of cytokines potentially linked to Th1 35 
memory cells (IFN-γ and TNF-α) in comparison to the ones from non-vaccinated dams. 36 
In conclusion, PCV2 sow vaccination, apart from triggering a humoral immunity 37 
response in sows and their progeny, might be associated to an increased transfer of cell-38 
mediated immunity from the dam to the piglet. 39 
 40 
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1. Introduction 43 
Porcine circovirus 2 (PCV2) is the etiological agent of several clinical or subclinical 44 
forms known as porcine circovirus diseases (PCVD) (Allan et al., 2002). Among these, 45 
PCV2-subclinical infection (PCV2-SI) is nowadays the most prevalent, representing the 46 
highest proportion of the negative economic impact at farm level in comparison to the 47 
other PCVDs (Alarcón et al., 2013). 48 
 49 
The benefits of dam vaccination on their progeny have been demonstrated in terms of 50 
reduction of PCV2-systemic disease (PCV2-SD) prevalence, viremia and PCV2 load in 51 
tissues (Opriessnig et al., 2010; Pejsak et al., 2010; Fraile et al., 2012; O'Neill et al., 2012). 52 
However, this strategy does not provide full protection against PCV2 infection in the 53 
offspring, as PCV2 vertical transmission in vaccinated sows can occur (Madson et al., 54 
2009a, b; Hemann et al., 2014). 55 
 56 
PCV2 vaccination elicits both humoral and cellular immune responses against PCV2 57 
(Fort et al., 2009; Martelli et al., 2011; Seo et al., 2014). In sows, the goal of vaccination 58 
before farrowing, is the protection of the offspring by means of maternal immunity 59 
transfer through colostrum. Several studies have shown the maternal antibody transfer 60 
from sows to piglets (Kurmann et al., 2011; Fraile et al., 2012; Sibila et al., 2013; Oh et 61 
al., 2014; Dvorak et al., 2017). Nevertheless, the passive transfer of the PCV2-specific 62 
cellular immune response to the offspring has hardly been investigated. To our 63 
knowledge, only one peer-reviewed study has demonstrated that maternally derived 64 
colostral lymphocytes from PCV2 immunized sows may be transferred to the progeny 65 
(Oh et al., 2012). In that study, the participation of these lymphocytes in the adaptive 66 
immune response was measured by in vivo delayed type hypersensitivity (DTH) 67 
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responses, in vitro lymphocyte proliferation and the presence of PCV2-specific IFN-γ-68 
secreting cells (IFN-γ-SCs) in new-born piglets. However, in this context, information on 69 
cytokine profiles in piglets after colostrum intake and the influence of sow vaccination 70 
on these profiles is not available. Therefore, the objective of the present work was to 71 
assess the effect of sow vaccination against PCV2 on humoral and cell-mediated 72 
immunity in sows and their offspring. 73 
 74 
2. Material and methods 75 
2.1. Farm selection 76 
The study was conducted in a commercial farm with 1,060 sows (Large White x 77 
Landrace) located in Spain. This farm was a two-site herd with all-in/all-out management 78 
and 4-week batch farrowing system. PCV2 vaccination in sows and piglets had never 79 
been applied in the herd under study. Sows were routinely vaccinated against Porcine 80 
reproductive and respiratory syndrome virus, Aujeszky's disease virus, Swine influenza 81 
virus, Porcine parvovirus, Erysipelothrix rhusiopathiae, Escherichia coli and 82 
Clostridium perfringens. Piglets were vaccinated against Mycoplasma hyopneumoniae at 83 
2 days pre-weaning. Weaning was performed at 3 weeks of age. Besides, PCVD clinical 84 
problems were never detected in this herd and the average of the reproductive parameters 85 
was within the Spanish one (www.bdporc.irta.es). Furthermore, no clinical signs of any 86 
other significant diseases were observed. 87 
 88 
In order to evaluate the PCV2 antibody levels in the sow herd, blood samples from 30 89 
sows from 2nd to 7th parity were taken and processed by ELISA (Ingezim Circo IgG 90 
11.PCV.K1®, Ingenasa, Madrid, Spain). PCV2 antibodies were detected in 29 out of 30 91 
(96.7%) sows, observing the highest ELISA S/P values in 5th parity sows (Figure 1). 92 
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 93 
2.2. Study design 94 
Fifteen healthy sows (parity 3-4th) with the same expected farrowing day were selected 95 
from the screened farm at 7 weeks pre-farrowing. These animals were individually ear-96 
tagged and bled. Blood samples were tested by conventional PCV2 PCR (Quintana et al., 97 
2002) and ELISA (Ingezim Circo IgG 11.PCV.K1®). All sows were PCR negative and 98 
showed low-medium (ranging from 0.27 to 0.85) ELISA S/P values. At 6 weeks pre-99 
farrowing, sows were randomly distributed in two treatment groups according to S/P 100 
values. Seven sows were vaccinated by intramuscular injection with 2 mL of a 101 
commercial inactivated PCV2 vaccine (CIRCOVAC®, Ceva) at 6 and 3 weeks pre-102 
farrowing. In parallel, eight non-vaccinated sows received 2 mL of phosphate buffer 103 
saline (PBS) at the same time points and by the same route. Animals with different 104 
treatments were comingled in the same gestation pens as well as in the same farrowing 105 
unit rooms. In sows, blood samples were taken in vacuum tubes by jugular venepuncture 106 
at 6 weeks pre-farrowing and at the farrowing week (Table 1). 107 
 108 
At birth, all piglets from litters of studied sows were ear-tagged and registered. Cross-109 
fostering was not allowed for the sows included in the study. At 48-72 hours after birth, 110 
blood samples from six healthy and medium-sized piglets per litter were taken in tubes 111 
without anticoagulant (n=90). In addition, from two of these six piglets selected per litter, 112 
blood samples were also taken in heparinized vacuum tubes (n=30). Once in the 113 
laboratory, blood samples in heparin tubes were immediately processed to obtain 114 
peripheral blood mononuclear cells (PBMCs), while the ones in tubes without 115 
anticoagulant were centrifuged at 750 g during 20 min to extract the sera. Sera were 116 
aliquoted and stored at -20ºC until testing. 117 
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 118 
Any abnormality related to general state, condition of the skin, hair and mucosa, 119 
respiratory, digestive and nervous signs, and locomotive problems was registered at 120 
different time points (Table 1) in both sows and piglets. Housing conditions, feeding 121 
system, feed characteristics and health management remained consistent along the course 122 
of the trial, and were the same for both experimental groups. The present study was 123 
approved by the Ethics Committee for Animal Experimentation from the Universitat 124 
Autònoma de Barcelona and the Animal Experimentation Commission from the local 125 
government (Dpt. de Medi Ambient i Habitatge from the Generalitat de Catalunya; 126 
Reference 9402). 127 
 128 
2.3. DNA extraction and conventional PCR 129 
DNA was extracted from 200 µL of serum by using the MagMAXTM Pathogen 130 
RNA/DNA Kit (Applied Biosystems) following the manufacturer´s instructions. DNA 131 
obtained was suspended in 90 µL of elution solution. Then, PCV2 genome was detected 132 
by standard PCR (Quintana et al., 2002). Each extraction and PCR plate included negative 133 
and positive controls, where samples were replaced for diethylpyrocarbonate (DEPC)-134 
treated water or known PCV2 infected sample, respectively. 135 
 136 
2.4. Indirect ELISA for measuring anti-PCV2 IgG antibodies 137 
All serum samples were tested by Ingezim Circo IgG 11.PCV.K1® assay (Ingenasa, 138 
Madrid, Spain). Optical density (OD) was measured at 450 nm by PowerWave XS reader 139 
(BioTek). Cut-off was established at 0.3 OD (± Standard Deviation [SD]) following kit´s 140 
instructions. ELISA results were expressed as mean S/P ratio (OD of sample/OD of 141 
positive control for each ELISA plate) ± SD. 142 
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 143 
2.5. Peripheral blood mononuclear cells (PBMCs) isolation and stimulation 144 
PBMCs were isolated from blood collected in heparinized tubes by density gradient 145 
centrifugation using Histopaque® 1.077 (Sigma, Madrid, Spain). PBMCs were washed 146 
and suspended in complete RPMI-1640 (Lonza, Barcelona, Spain) (cRPMI) plus 10% 147 
foetal bovine serum (FBS) (Sigma, Madrid, Spain); cell viability was assessed with 148 
Trypan blue staining. Then, PBMCs were seeded into 96-well plates (1 x 106 cells/well) 149 
and incubated with baculovirus-expressed PCV2 Cap protein (final concentration per 150 
well: 0.6 µg/mL); phytohemagglutinin (Sigma, Madrid, Spain) (final concentration per 151 
well: 10 µg/mL) as a positive control; or cRPMI plus 10% FBS as a negative control for 152 
24 h at 37°C in a 5% humidified CO2 atmosphere. After incubation, plates were 153 
centrifuged and cell culture supernatants were collected and stored at -80ºC until further 154 
examination. 155 
 156 
2.6. Multiplex immunoassay for the quantification of cytokines 157 
PBMC supernatant samples were analysed using ProcartaPlex Porcine Cytokine & 158 
Chemokine Panel 1 (Affymetrix, eBioscience, Vienna, Austria) according to the 159 
manufacturer’s instructions. This multiplex immunoassay uses Luminex® xMAP 160 
technology for the quantification of 9 cytokines: IFN-α, IFN-γ, IL-12p40, TNF-α, IL-1β, 161 
IL-8, IL-4, IL-6 and IL-10. The plates were read by a MAGPIX® analyser (Luminex 162 
Corporation) and the cytokine levels were determined according to standard curves using 163 
xPONENT® 4.2 software (Luminex Corporation). Then, for the final calculation of 164 
PCV2-specific cytokine secretion (pg/mL), cytokine levels in supernatants from PBMCs 165 
with medium (background) were subtracted from cytokine levels in supernatants from 166 
PBMCs stimulated with PCV2 Cap protein. 167 
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 168 
2.7. Statistical analyses 169 
Statistical analyses were carried out using StatsDirect v3.1.1. Kruskal–Wallis test was 170 
used for comparisons of ELISA S/P values and cytokine levels between groups and 171 
between sampling points. Significance level was set at p≤0.05. 172 
 173 
3. Results 174 
3.1. Clinical signs and detection of PCV2 DNA in serum samples from sows and piglets 175 
No evident clinical signs were observed in sows or piglets throughout the study. All sows 176 
(15 out of 15) and piglets (90 out of 90) were PCR negative during all the study duration. 177 
 178 
3.2. Anti-PCV2 IgG antibody levels in sow and piglet serum samples 179 
Mean S/P levels (± SD) in sows and their offspring for both treatment groups are 180 
represented in Figure 2. From 7 weeks before farrowing to farrowing week, vaccinated 181 
sows showed an increase of ELISA S/P values, resulting in significantly higher (p<0.05) 182 
antibody levels compared to the ones from the non-vaccinated sows at farrowing. 183 
Moreover, piglets from vaccinated sows also had significantly higher S/P values than the 184 
ones from non-vaccinated counterparts at 48-72 hours of life. 185 
 186 
3.3. Cytokine levels 187 
3.3.1. PBMC supernatant samples in sows 188 
PCV2-specific cytokine concentrations for sows of the two treatment groups are shown 189 
in Figure 3. No statistically significant differences were observed when comparing 190 
vaccinated and non-vaccinated groups at each sampling point (pre- and post- treatment 191 
injection) in any of the tested cytokines. 192 
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 193 
3.3.2. PBMC supernatant samples in piglets 194 
PCV2-specific cytokine values in piglets at 48-72 hours after birth are summarized in 195 
Figure 4. Piglets born from vaccinated sows had significantly (p≤0.05) higher levels of 196 
IFN-α, IFN-γ, TNF-α and IL-1β than the ones from control group. Regarding the IL-8, 197 
very high values close to the upper detection limit of the technique were found in both 198 
groups (without significant differences). In the rest of the cytokines (IL-12p40, IL-4, IL-199 
6 and IL-10), no significant differences were found between groups. 200 
 201 
4. Discussion 202 
The main goal of the present work was to describe the cytokine profiles in piglets born 203 
from vaccinated sows in comparison to the ones from unvaccinated sows. In the present 204 
study, piglets from vaccinated sows had significantly higher levels of IFN-γ, suggesting 205 
that these animals had memory T cells able to produce IFN-γ upon stimulation with a 206 
PCV2 antigen. These findings were correlated with a previously study (Oh et al., 2012), 207 
where significantly higher levels of IFN-γ-SCs were observed in piglets from vaccinated 208 
sows with regard to the ones from unvaccinated sows after colostrum ingestion. The 209 
assessment of IFN-γ-SCs is commonly used to measure the cell-mediated immunity 210 
response, mainly for the following reasons: 1) the levels of PCV2 specific IFN-γ-SCs 211 
increase after infection and vaccination (Fort et al., 2009; Koinig et al., 2015); in fact, 212 
PCV2 vaccination induces a long-lasting immunity sustained by memory T cells and IFN-213 
γ secreting cells that might participate in the prevention of PCV2 infection (Ferrari et al., 214 
2014); 2) IFN-γ-SCs are inversely correlated with PCV2 viral loads in serum (Seo et al., 215 
2012a; Seo et al., 2012b); and 3) these T cells are specific for both PCV2 Cap and Rep 216 
proteins (Fort et al., 2010). However, to the authors’ knowledge, information about 217 
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general cytokine profiles in piglets after colostrum ingestion is missing in the peer-218 
reviewed literature. 219 
 220 
In the present study, piglets from vaccinated sows also had significantly higher levels of 221 
TNF-α, IFN-α and IL-1β. Especially relevant is the case of TNF-α, since the production 222 
of TNF-α simultaneously with that of IFN-γ by T cells after PCV2 vaccination has been 223 
potentially correlated with protection (Koinig et al., 2015). In that study, the induction of 224 
PCV2-specific antibodies after PCV2 piglet vaccination was only observed in five out of 225 
12 animals. However, at this time point, all vaccinated pigs showed IFN-γ/TNF-α co-226 
producing T cells and all vaccinated piglets were fully protected against viremia after 227 
subsequent challenge (Koinig et al., 2015). Regarding the other two cytokines (IFN-α and 228 
IL-1β), these are not linked to memory T lymphocytes, since they are produced by other 229 
cell types (mainly macrophages and dendritic cells) primarily involved in innate 230 
immunity response (Chase and Lunney, 2012). Therefore, these significant differences 231 
observed between groups could be due to differences in the proportion of cell populations 232 
in PBMCs from each group, although these cellular subpopulations have not been tested 233 
in the present trial. Another more direct way to evaluate the transfer of immune cells 234 
would have been to analyse the colostrum, testing PCV2-specific cell subpopulations or 235 
cytokine (mainly IFN-γ) secretion, as previously described (Oh et al., 2012). However, 236 
given the difficulty of isolating colostral cells, the present study offers a more practical 237 
(PBMC isolation and stimulation) and quick (Multiplex immunoassay for the 238 
quantification of different cytokines at the same time) method to assess indirectly but 239 
apparently reliably the potential transfer of cellular immunity to the offspring. 240 
 241 
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On the other hand, the same cytokine profiles were tested in sows before and after 242 
treatment application. The cell-mediated immune response after PCV2 vaccination has 243 
been minimally investigated in sows. In a previously published trial (Oh et al., 2012), 244 
vaccinated sows showed an increase in the proportions of T lymphocytes (CD4+, CD8+ 245 
and CD4+CD8+) at 1 day post-partum, attributing these changes to PCV2 vaccination. 246 
This higher proportion of immunological T cells in vaccinated sows might be related to a 247 
higher excretion of cytokines linked to memory response; however, in the present study, 248 
although vaccinated sows showed higher levels in almost all tested cytokines with regard 249 
to the non-vaccinated ones, these differences were not statistically significant, most 250 
probably due to the low number of sampled sows (7-8 sows per group). 251 
 252 
In order to complement the cellular immunity results, active (sows) and passive (piglets) 253 
humoral immunity was also evaluated in this study. In sows, PCV2 vaccination twice 254 
before farrowing produced an increase of antibody values in comparison to the non-255 
vaccinated counterparts. This humoral response after immunization was observed in other 256 
studies when sows were vaccinated before mating or farrowing (Gerber et al., 2011; Sibila 257 
et al., 2013). In the present work, vaccinated sows had higher levels of antibodies in blood 258 
at farrowing. This fact triggered a greater transfer of maternal antibodies to the piglets, 259 
which were evident after colostrum ingestion, as was also detected in an earlier study 260 
(Kurmann et al., 2011). 261 
 262 
In conclusion, PCV2 vaccination at 6 and 3 weeks pre-farrowing elicited high antibody 263 
values in sows at farrowing and in their offspring. Moreover, piglets from vaccinated 264 
sows had significantly higher levels of cytokines potentially linked to Th1 memory 265 
response (IFN-γ and TNF-α), suggesting that this vaccination strategy may confer PCV2 266 
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specific cell-mediated passive immunity to the progeny. Nevertheless, more research is 267 
needed in order to study in depth the transfer of maternal lymphocytes through colostrum 268 
as well as the role of the cytokines secreted by them in the new-born piglet. 269 
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10. Figure Legends 390 
Figure 1. Individual PCV2 ELISA S/P results in serum samples from sows with different 391 
parity number prior to the start of the study (farm screening). 392 
 393 
Figure 2. PCV2 ELISA S/P results (mean±SD) in serum samples taken from the sows 394 
included in the study and their offspring at different time points. Different letters in 395 
superscript mean statistically significant differences among experimental groups at each 396 
sampling point (a>b; p<0.05). 397 
 398 
Figure 3. PCV2-specific cytokine secretion (pg/mL) in PBMC supernatant samples from 399 
sows. In each graphic, the two boxes from the left correspond to the first sampling point 400 
(6 weeks pre-farrowing); the two boxes from the right correspond to the second sampling 401 
point (farrowing). The “x” symbol indicates the mean. No statistically significant 402 
differences were observed among vaccinated (V) and non-vaccinated (NV) sows at each 403 
time point. 404 
 405 
Figure 4. PCV2-specific cytokine secretion (pg/mL) in PBMC supernatant samples from 406 
piglets at 48-72 hours after birth. The “x” symbol indicates the mean. *Statistically 407 
significant differences (p≤0.05) among piglets born from vaccinated (V) and non-408 
vaccinated (NV) sows. 409 
 410 
 411 
 412 
 413 
